Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial

F Barlesi; JS Ahn; BJ Solomon; M Nishio; R Dziadziuszko; DH Lee; JS Lee; W Zhong; H Horinouchi; W Mao; M Hochmair; F de Marinis; MR Migliorino; I Bondarenko; T Xu; I Bara; B Ding; C Ngiam; P Petric; YL Wu

Journal article

Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial

F Barlesi, JS Ahn, BJ Solomon, M Nishio, R Dziadziuszko, DH Lee, JS Lee, W Zhong, H Horinouchi, W Mao, M Hochmair, F de Marinis, MR Migliorino, I Bondarenko, T Xu, I Bara, B Ding, C Ngiam, P Petric, YL Wu

Lung Cancer | Elsevier BV | Published : 2026

DOI: 10.1016/j.lungcan.2026.109385

Open access

Abstract

Objectives: This exploratory analysis investigated whether the disease-free survival (DFS) benefit seen with adjuvant alectinib versus chemotherapy in patients with resected, ALK-positive non-small cell lung cancer (NSCLC) from the phase III ALINA study (NCT03456076) was maintained across surgical characteristic subgroups and when re-classifying patients according to the 8th edition of the Cancer Staging Manual of the American Joint Committee on Cancer (AJCC) and Union for International Cancer Control (UICC). Methods: ALINA is a global, open-label, randomized trial. Eligible patients ≥ 18 years old with resected, ALK-positive NSCLC of stage IB (≥4 cm), II, or IIIA (per AJCC/UICC 7th edition)..

View full abstract